[Webinar] [FR] How do we keep you in the race of COVID-19?

[Webinar] HOW DO WE KEEP YOU IN THE RACE OF COVID-19?

[Webinar] HOW DO WE KEEP YOU IN THE RACE OF COVID-19?

AFSSI Digital Week - 16 October 2020 - 2pm - CEST


Infectious diseases are caused by pathogenic micro-organisms, such as bacteria, viruses, parasites or fungi; diseases can be transmitted, directly or indirectly, from one person to another.Infectious diseases are caused by pathogenic micro-organisms, such as bacteria, viruses, parasites or fungi; diseases can be transmitted, directly or indirectly, from one person to another.

Three infectious diseases have been ranked among the top ten causes of death worldwide in 2016 by the World Health Organization. These are lower respiratory tract infections (3.0 million deaths), diarrhoeal diseases (1.4 million deaths) and tuberculosis (1.3 million deaths).

Despite significant progress in research and treatments for infectious diseases, the control and eradication of these diseases still face major challenges.

We are currently facing a new emerging infectious disease with the global COVID-19 outbreak caused by the SARS-CoV-2 virus, a type of coronavirus part of a group of RNA viruses (that cause diseases in mammals and birds). Both public research and pharmaceutical industry have been mobilized to find ways to speed up the launch of prophylactic or therapeutic solutions. We have to be SMART to win the race against COVID-19. Different options can be considered, such as substantial investments, drug repositioning, massive consolidation of pharmaceutical companies.

Faced with this fast-paced demand from the pharmaceutical industry, the CROs are coming together to respond quickly and ingeniously to this unprecedented health crisis.

Come and listen to Innovative Providers’ solutions. We will unveil our continuum of specialties to unlock the scientific padlocks linked to Covid-19.

Key learning objectives

  • Panorama of Emergent & Infectious Disease
  • The ongoing COVID-19 outbreak
  • Challenges to overcome ​to find a solution against Covid-19​
  • Our scientific & smart specialties to keep you in the race

Discover our speakers

I registrer online

[Congress] Bio Europe, October 26-29, 2020

[Congress] Bio Europe, October 26-29, 2020

This is time to choose your scientific partner, that is why we propose you to discover our integrated drug discovery & development solution.

An integrated drug discovery & development solution from hit finding to IND filing in less than 3 years

DRIVE™ is part of Oncodesign’s continuous commitment to improve its integrated drug discovery offer DRIVE™.
This joint offering encompasses all drug discovery skills, expertise and platforms to deliver drugs in major therapeutic areas including oncology, immuno-oncology, immuno-inflammation and inflammation.
DRIVE™ runs a multiparametric optimization mode, with streamlined and fast testing of newly synthesized compounds. By applying immediate processing, within a collaborative environment between medicinal chemists, in vitro/in vivo pharmacologists and DMPK specialists, Oncodesign helps reduce the iterative cycles of optimization to rapidly deliver preclinical candidates.

DRIVE™ premium solution timeline

DRIVE™ premium solution timeline

Our expert Emily Fang will participate to give you the answers you need to make the right decisions at the right time for success in your drug discovery journey.

Let's engage a conversation with Emily!

STREAM OUR WEBINAR

Meet with Dr. Holfack to discuss the terms of a possible collaboration to further develop together our Kinase inhibitor development products based on Nanocyclix® technology.

Schedule a meeting with Dr. Hoflack

[Congress] European Association of Nuclear Medicine Annual Meeting , October 22 – 30 EANM 2020

[Congress] European Association of Nuclear Medicine Annual Meeting , October 22 – 30 EANM 2020

The EANM Annual Congress is the most valuable Nuclear Medicine Meeting worldwide. This is the place to be to engage conversation about the latest and newest trends and outcome in Nuclear Medicine.

It takes 2 to tango: compound labeling and complementary imaging approaches to show how your compound works & targets the right patient.

Through pharmaco-imaging, the results of preclinical studies can influence the early decision to continue or interrupt the development of a drug candidate.
In the clinical development phase, imaging offers an exceptional opportunity to follow the drug in humans with the same techniques developed during the preclinical phase.
Novel therapies are converging towards precision medicine, for which pharmaco-imaging is indispensable to all players in the drug development cycle – from the pharmaceutical industry to clinicians – to ensure that the most appropriate treatments are being matched to the needs of the patient.

Explore our multi-modal pharmaco-imaging & targeted radiotherapy expertise for your preclinical projects:

  • Design & implementation of the radionuclide labeling of your chemical or biological molecules of interest
  • Biodistribution of therapeutic drugs using non-invasive techniques
  • Development of translational nuclear medicine biomarkers
  • Evaluation of targeted radiotherapy efficacy

Schedule a meeting with Cyril!

[Congress] Bio Japan, October 14-16, 2020

[Congress] Bio Japan, October 14-16, 2020

Bio Japan is Asia's Premier Partnering Event for the Global Biotechnology Industry.
It has played an important role in facilitating interaction between Japanese and global companies/organizations and stimulating new business opportunities for almost two decades. It focuses on the new researchers who have come up with innovations which would help in the future of mankind.

Choose innovation, choose Oncodesign.
We create an integrated drug discovery & development solution to help you from the early phases up to IND (Investigational New Drug)

An integrated drug discovery & development solution from hit finding to IND filing in less than 3 years

DRIVE™ is a smart and agile solution to help clients streamline their drug discovery and development programs and to make best use of their resources and achieve optimum results.
DRIVE™ offers a complete drug discovery and development solution through the whole value chain from hit finding to IND filing, aiming to accelerate the entry of the client new chemical entities into clinic within a 3 to 4 years timeframe to deliver an IND.

DRIVE™ premium solution timeline

DRIVE™ premium solution timeline

Our expert Emily Fang will participate to give you the answers you need to make the right decisions at the right time for success in your drug discovery journey.

Let's engage a conversation with Emily!

STREAM OUR WEBINAR

Dr. Hoflack will be introducing our Nanocyclix® products pipeline to open up a path to new kinases of therapeutic interest. He is thrilled to discuss any partnership opportunities to welcome on you onboard.

Schedule a meeting with Dr. Hoflack